In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklud, CEO of Circio and Jacob Becraft, CO-founder and CEO of Strand Therapeutics.

Since the mRNA vaccine breakthroughs of the COVID-19 era, attention has turned to what's next for programmable medicines. While first- generation mRNA prove the power of transient genetic instruction, its instability, immune reactivity, and short-lived expression have limited its use mainly to vaccines. Emerging platforms like circular and logic circuit RNA are expanding the field's therapeutic horizons.

Host

Jennifer Smith-Parker, Director of Insights, BioSpace

Guests

Erik Digman Wiklund⁠, CEO, Circio

Jacob Becraft, Co-founder and CEO, Strand Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.